AbCellera Biologics (ABCL) Stock Price, Quote, News & History | Benzinga

SPY767.99+0.52%QQQ748.25+0.84%BTC/USD86,209.41+1.60%DIA511.20+0.51%GLD383.12+0.09%TLT77.68−0.04%

AbCellera Biologics Inc (ABCL) Stock Price, Quote, News & History

ABCLNASDAQ

Trade with Public

Trade with Public

$13.91

-0.68-4.66%

Last update: Oct 2, 4:44 AM

$14.01

-0.58-3.98%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$13.91

Volume / Avg.

12.13K / 6.84M

Day Range

- - -

52 Wk Range

2.75 - 15.02

Market Cap

$4.54B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

66

Short Interest

13.34%

Days to Cover

9.63

Recent AbCellera Biologics Inc. News

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.

Vandana Singh

Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.

Avi Kapoor

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst price targets point to further upside.

Vandana Singh

National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.

Avi Kapoor

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera reports positive Phase 2 clinical trial results for ABCL635, a single-dose treatment for menopausal hot flashes.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-94.94M

Investing Cash Flow (TTM)

97.89M

Financing Cash Flow (TTM)

25.07M

Free Cash Flow (TTM)

-119.67M

Capital Expenditure (TTM)

-24.73M

Net Change in Cash (TTM)

28.02M

Analyst Trends and Forecast

1

Apr

1

May

1

Jul

3

Aug

1

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.7

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$4.10B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

63.47

PB Ratio (TTM)

5.03

Earnings Yield % (TTM)

-3.88%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.77

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$120.07M

Debt to Equity

0.15

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-